The graft-versus-tumor (GVT) effect after allogeneic bone marrow transplantation (BMT) can potentially cure many hematopoietic malignancies. Its applicability has been limited by its major complication, graft-versus-host disease (GVHD). In this study, we show the relevance of cytokine IL-6 and its blockade with anti-IL-6R monoclonal antibody (mAb) on experimental GVT and GVHD in multiple clinically relevant models of BMT. Our data, consistent with clinical observations, demonstrate elevation of serum levels of IL-6 in the hosts after allogeneic bone marrow transplantation (BMT). Donor T cell-derived IL-6 contributed to GVHD severity.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HSCT) is one of the curative therapeutic options for hematological malignancies and solid tumors (1) . The mechanism of tumor eradication in allogeneic HSCT recipients is the immune-mediated graft-versus-tumor (GVT) effect. The host hematopoietic system is reconstituted with donor hematopoietic system and donor lymphocytes, especially T cells that have the potential to exert GVT effects concurrently with graft-versushost disease (GVHD) (2, 3) . Clinical data have demonstrated that the severity of GVHD is correlated with chance of relapse (1, 4) . Acute GVHD is a major side effect of allogeneic HSCT including bone marrow transplantation (BMT) (1, 5) .
A large number of pro-inflammatory cytokines are involved in the pathophysiology of GVHD.
The presence of a pro-inflammatory milieu is attributable to the (a) conditioning regimen, (b) the allo-reaction, and (c) the damage induced in the host tissues as a consequence of them both (5, 6) . Several inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are elevated after allogeneic BMT and known to perpetuate GVHD through either direct cytotoxic effects on host tissues (6) or by activation and/or priming of immune effector cells (7. Blockade of these cytokines modulated the severity of GVHD in mice and humans while several lines of experimental evidence suggest that appropriate intervention with cytokine blockade GVT {Hill, 1999 #27401, 8).
IL-6 is known to have broad effects, including maturation and activation of B cells, T cells, and macrophages (9) . IL-6 has been directly implicated in many experimental and human inflammatory diseases (9) . Blockade of IL-6 signaling with anti-IL-6R mAb demonstrated salutary effects in mouse models of several inflammatory diseases (9, 10) . More interestingly, blockade of IL-6 with tocilizumab, a humanized monoclonal antibody (mAb) specific for IL-6 receptor (IL-6R), has been shown to have therapeutic effects in many human diseases, such as 6 rheumatoid arthritis, Castleman's disease, and juvenile idiopathic arthritis (9, (11) (12) (13) .
Tocilizumab is now approved for clinical use in the United States, the European Union, and other countries (14) .
Several lines of correlative data and indirect evidence suggest that IL-6 may be relevant in the induction and severity of GVHD. For example, IL-6 polymorphisms in the recipients of HLAmatched sibling transplants have been found to be associated with acute and chronic GVHD (15) , while serum levels of IL-6 have been found to be elevated in patients with acute GVHD (16) . Infusion of exogenous IL-6 has been shown to exacerbate (17) , while against the IL-6 receptor (IL-6R) reduced experimental GVHD (18) . However, the source of IL-6, whether it plays a direct pathogenic role in GVHD and the impact of its blockade on the critical GVT effects after allogeneic BMT are not known (18) (19) (20) (21) . In independent and parallel experiments performed in different laboratories across two countries, we utilized a combination of genetic and antibody blockade approaches in multiple strain models to demonstrate that IL-6 plays an important role in the severity of GVHD and that its blockade can ameliorate GVHD without leading to a complete loss of GVT responses. Given the safety and efficacy of IL-6 blockade in the treatment of several immunological diseases in humans (22) , our data suggest that targeting IL-6 with tocilizumab might be an immediately testable strategy in humans to mitigate acute GVHD without losing the significant anti-tumor benefits of allogeneic BMT. GVT experiments (24, 25) .
7

MATERIALS and METHODS
Mice
Bone marrow transplantation and antibody treatment: T cells from B6, C3H.SW, BALB/c or GFP-FoxP3 donors were enriched by AutoMACS using CD90-microbeads, Pan T cell isolation kit or CD8 isolation kit (Miltenyi, Auburn, CA). Recipient mice were irradiated ( 137 Cs source) with 8 -10 Gy total body irradiation (TBI) 1 day before or on the same day as the bone marrow transplant (BMT). Syngeneic or allogeneic T cell-depleted bone marrow (5x10 6 ) and isolated T cells were infused through the tail vein. Anti-mouse IL-6R (MR16-1) or control rat IgG (Sigma, St
Louis, MO) (0.5 mg/dose) were given to BMT hosts intravenously on day -1 and day 3 of BMT time course (26) . Mice were housed in sterilized microisolator cages and maintained on acidified water (pH < 3) for 3 weeks as described previously (25, 27) . Survival was monitored daily.
Clinical GVHD was assessed weekly as described previously (25, 27 Cytokine analyses with intracytoplasmic staining and ELISA: Cytokine levels of IL-6 IFN-γ, TNF-α, IL-4, IL-10, and IL-5 in sera or culture supernatant cytokines were determined by either cytokine bead array (BD Biosciences, CA) or by ELISA (BD Pharmingen) per manufacturer's instructions (30, 31) . Intracellular cytokines were determined in the donor CD4 T cell fractions by flow cytometry. Splenocytes from day 7 post-BMT recipients were stimulated with soluble anti-CD3e mAb (2 µg/ml) and brefeldin A (Biolegend, San Diego, CA) at 1/1000 dilution for 4
hours. Cells were processed for intracellular cytokine staining according to manufacturer's protocol (BD Cytofix/ Cytoperm Kit; BD Pharmingen).
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T cells (1x10 6 ) from wild type (WT) B6 or IL-6 KO mice with WT B6 TCD bone marrow. As shown in Fig. 1C , the absence of donor-derived IL-6 from T cells also resulted in a similar and significant delay in GVHD mortality (P<0.002) although, eventually, all recipients died from GVHD. These data demonstrated that donor T cell-derived IL-6 contributes to the overall severity of GVHD.
Because IL-6 can modulate the expansion or differentiation of T effector cells (9, 10, 37) and and TNF-α(data not shown). These data collectively show that significant and consistent differences in the polarization of donor T cells were not observed.
Consistent with an equivalent increase of donor T cells, no differences were observed in the expansion of donor Foxp3+ T cells in the spleens (Supplemental Fig. 1 ). Collectively these data
show that donor T cell-derived IL-6 plays a significant role in enhancing the severity of GVHD but does not alter donor T cell expansion or the amount of Th1 and Th17 cytokines that have been shown to play pathogenic roles in GVHD.
Given the overall importance of the combined (BM and T cells) donor-derived IL-6 ( Fig. 4 A, B) . The reduction in GVHD with the administration of anti-IL-6R mAb was also associated with a reduction in the GVHD specific hisopathological severity of the target organ, GI tract after allogeneic BMT ( Figure 4C ).
IL-6 blockade does not alter the T effector to Treg ratio
Because data with IL-6-/-grafts demonstrated equivalent expansion and differentiation of T effector cells ( BMT. Nonetheless, the thymic dependence of this process makes this a very unlikely cause for the protection seen early after BMT following IL-6 neutralization.
Effect of IL-6 on GI epithelium
Because of the lack of direct effect of IL-6 on either the cellular mediators, namely the infused mature donor Tregs and on the expansion or differentiation of alloreactive T cells, or on the inflammatory mediators (INF-γ, TNFα, IL-17 and IL-4) of acute GVHD, we next examined whether IL-6 has direct cytopathic effect on the GVHD target tissues. The intestinal epithelial tissues were harvested as in Materials and Methods and then exposed ex vivo to IL-6. The direct toxic effect of IL-6 was analyzed by staining these cells for apoptosis. As shown in Figure   5C , IL-6 caused a significant increase in the degree of apoptosis when compared to diluent treated controls. To further confirm the in vivo relevance of these observations, we lethally irradiated naïve B6 animals and treated them with MR16-1 as above. The intestinal tracts were then harvested 24 hours later and analyzed for amount of epithelial apoptosis. Blockade of radiation induced endogenous IL-6 by MR16-1 reduced the amount of intestinal epithelial cell apoptosis (Supplemental Figure 4) . Together these data demonstrate that IL-6 has direct toxic effect of GVHD target organ, the intestinal tract.
IL-6 blockade retains sufficient GVT responses
Because donor T cells are required for GVT responses, the maintenance of donor T cell effector responses to host antigens after anti-IL6R mAb treatment suggested that this approach might preserve at least some of the beneficial GVT activity. To directly examine the impact of IL-6
inhibition on GVT effect, we determined tumor-free survival in the allogeneic and syngeneic recipients after treatment with anti-IL-6R mAb (MR16-1 mAb did not alter T cell activity to host antigens and thus preserved sufficient GVT effects.
The induction of acute GVHD is a direct consequence of donor T cell responses to host alloantigens and the deregulation of pro-inflammatory cytokines (6).The pro-inflammatory
cytokines such as IL-1 and TNF-α have been shown to play a direct role in enhancement of GVHD by causing direct damage to gut mucosa and by modulating donor T cell responses (6, 7). IL-6, also a known pro-inflammatory cytokine, is elevated after clinical allogeneic BMT (18, (33) (34) (35) . Moreover, IL-6 gene polymorphism studies have shown an association with increased GVHD severity after allogeneic BMT (15). These observations, however, do not address whether IL-6 plays a direct role in causing or amplifying GVHD severity. Furthermore, it is also not known whether the source of IL-6 is critical for GVHD. In the current study, we demonstrate that reduction of IL-6 secretion or its effects by its receptor blockade reduced GVHD across multiple models. IL-6 is produced by numerous cell types and the effects of IL-6 are varied depending on the type of responding cells and whether they are activated directly or in trans (9, 43) . Our data suggest that while donor T cells are the most significant source of IL-6 production for increasing GVHD severity, global blockade of its activity induced significantly better GVHD A recent study has shown that blockade of IL-6 increases the numbers of donor Tregs as a direct consequence of peripheral conversion, as well as from the donor BM (18) . Our data confirm and extend the observations from that study in demonstrating an important role for GVHD. However, in contrast to the earlier study, we show that a brief duration of IL-6 inhibition did not increase the absolute numbers of mature donor Tregs (18) . This could be a consequence of the several key differences between the models, including the dose of radiation, the infusion of unsorted splenocytes (we used purified donor T cell subsets), and the longer duration of the IL-6 blockade (18). In addition, we also found a similar lack of increase in donor mature Tregs despite the reduction in GVHD severity when T cells from IL-6-/-mice were used as donors. It is also important to note that in contrast to Chen et al, we only focused on the role of mature Tregs, and our data do not directly explore the development or the role for donor 
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GVHD is likely a consequence of direct reduction in IL-6 induced inflammation and cytopathic damage of the target tissues (43) (44) (45) (46) (47) . Our findings extend previous work (17, 18) and show that IL-6 blockade attenuates GVHD across multiple models under a variety of experimental BMT conditions.
The toxicity of GVHD is difficult to separate from GVT effects, a well-recognized benefit of immunotherapy for malignancies (1) (2) (3) (4) . Inflammatory cytokines significantly contribute to the toxicity of GVHD but have a more limited role in the eradication of residual leukemia, which is primarily mediated by donor cytotoxic T lymphocytes and NK cells in BMT experimental models using established tumor cell lines (48) . Thus, inhibition of IL-6 leads to disruption of the direct inflammatory effects of IL-6 while maintaining donor T cell functions and thereby successfully preserving sufficient GVT responses in two different strain and tumor models. However, the GVT models have certain limitations (48) . For example, the tumor cell lines, despite exhibiting the classic hallmarks (49) , may demonstrate variability in subcloning efficiency and outgrowth of dominant clones that likely alter the nature, immunogenicity, and density of relevant antigens (48) . Moreover, the immune repertoire of tumors that develop in these models, unlike in humans, is more homogenous and not subjected to immunoediting (50) . Nonetheless, such tumor systems have been useful in elucidating the effector mechanisms of immunotherapy and GVT activity (48) .
Our findings demonstrate a direct role for IL-6 in the severity of GVHD and show that its brief inhibition early after allo-BMT reduces GVHD while preserving donor T cell responses and meaningful GVT effects. Because anti-IL-6R mAb (tocilizumab) is now FDA approved, and is currently being tested in phase I/II clinical trials in human cancer patients (13, 14, 22, 51) , it may soon be testable in allogeneic BMT recipients as an anti-inflammatory adjunct to standard Supplemental Figure 3 
